Eric W. Thomas

Array ( [id] => 11948278 [patent_doc_number] => 20170252429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'Direct Method for providing Immunological Memory against HIV' [patent_app_type] => utility [patent_app_number] => 15/426055 [patent_app_country] => US [patent_app_date] => 2017-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 6982 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15426055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13867633 [patent_doc_number] => 20190030157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => Compositions and Methods for Generating an Immune Response to a Flavivirus [patent_app_type] => utility [patent_app_number] => 16/074947 [patent_app_country] => US [patent_app_date] => 2017-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16074947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16665112 [patent_doc_number] => 10934345 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-02 [patent_title] => Broadly neutralizing antibodies against HIV-1 and use thereof [patent_app_type] => utility [patent_app_number] => 16/075211 [patent_app_country] => US [patent_app_date] => 2017-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 10832 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16075211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17844907 [patent_doc_number] => 11434259 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-06 [patent_title] => Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity [patent_app_type] => utility [patent_app_number] => 16/072357 [patent_app_country] => US [patent_app_date] => 2017-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 64920 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16072357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13955635 [patent_doc_number] => 20190054161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => INACTIVATED VACCINE FOR CHIKUNGUNYA VIRUS [patent_app_type] => utility [patent_app_number] => 16/069073 [patent_app_country] => US [patent_app_date] => 2017-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6136 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16069073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13790579 [patent_doc_number] => 20190008828 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => METHODS FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS (HIV) RELEASE FROM INFECTED CELLS [patent_app_type] => utility [patent_app_number] => 16/065854 [patent_app_country] => US [patent_app_date] => 2016-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11713979 [patent_doc_number] => 20170182478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-29 [patent_title] => 'ADSORBENT AND METHOD FOR PRODUCING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/384326 [patent_app_country] => US [patent_app_date] => 2016-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8328 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15384326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618795 [patent_doc_number] => 20180360949 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => IMMUNOGENIC COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/061729 [patent_app_country] => US [patent_app_date] => 2016-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13298 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16061729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14662675 [patent_doc_number] => 10369214 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-06 [patent_title] => Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof [patent_app_type] => utility [patent_app_number] => 15/380123 [patent_app_country] => US [patent_app_date] => 2016-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 19549 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15380123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11714887 [patent_doc_number] => 20170183387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-29 [patent_title] => 'METHODS AND COMPOSITIONS FOR SUPPRESSING RETROVIRUSES' [patent_app_type] => utility [patent_app_number] => 15/364184 [patent_app_country] => US [patent_app_date] => 2016-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4731 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15364184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13577213 [patent_doc_number] => 20180340155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => LIVE VIRUS HAVING A BANK OF DENGUE VIRUS ATTENUATED STRAINS, AND A DENGUE VACCINE CONTAINING SAME AS ANTIGENS [patent_app_type] => utility [patent_app_number] => 15/778368 [patent_app_country] => US [patent_app_date] => 2016-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14758 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15778368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12486825 [patent_doc_number] => 09993546 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-12 [patent_title] => Lysosomal targeting of antigens employing nucleic acids encoding lysosomal membrane polypeptide/antigen chimeras [patent_app_type] => utility [patent_app_number] => 15/353847 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 26 [patent_no_of_words] => 27863 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15353847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14043485 [patent_doc_number] => 20190077849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => NEUTRALIZING ANTIBODIES TO HIV-1 GP41 AND THEIR USE [patent_app_type] => utility [patent_app_number] => 15/772443 [patent_app_country] => US [patent_app_date] => 2016-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15772443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14662693 [patent_doc_number] => 10369223 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-06 [patent_title] => Single domain antibodies directed against ebola virus VP24 [patent_app_type] => utility [patent_app_number] => 15/342044 [patent_app_country] => US [patent_app_date] => 2016-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 7952 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15342044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13885491 [patent_doc_number] => 10195277 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-05 [patent_title] => Single domain antibodies directed against human immunodeficiency virus [patent_app_type] => utility [patent_app_number] => 15/342032 [patent_app_country] => US [patent_app_date] => 2016-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 7993 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15342032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11443550 [patent_doc_number] => 20170044571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'CHIMPANZEE ADENOVIRAL VECTOR-BASED FILOVIRUS VACCINES' [patent_app_type] => utility [patent_app_number] => 15/339225 [patent_app_country] => US [patent_app_date] => 2016-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 10318 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15339225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13504769 [patent_doc_number] => 20180303927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => RECOMBINANT MOPEIA VIRUS AND VACCINE PLATFORM [patent_app_type] => utility [patent_app_number] => 15/770210 [patent_app_country] => US [patent_app_date] => 2016-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14137 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15770210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13035415 [patent_doc_number] => 10039820 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-07 [patent_title] => West nile virus vaccine comprising WN-80E recombinant subunit protein [patent_app_type] => utility [patent_app_number] => 15/331596 [patent_app_country] => US [patent_app_date] => 2016-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8031 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15331596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393939 [patent_doc_number] => 20170014474 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'SCREENING METHOD FOR THE IDENTIFICATION OF AGENTS CAPABLE OF ACTIVATING CD4+CD25+ REGULATORY T-CELLS THROUGH INTERACTIONS WITH THE HIV-1 GP120 BINDING SITE ON CD4' [patent_app_type] => utility [patent_app_number] => 15/285561 [patent_app_country] => US [patent_app_date] => 2016-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 17630 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929103 [patent_doc_number] => 20190048067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => HIV ANTIBODY COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/762442 [patent_app_country] => US [patent_app_date] => 2016-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15762442 [rel_patent_id] =>[rel_patent_doc_number] =>)